Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Rhea-AI Summary
Jupiter Neurosciences (NASDAQ:JUNS) signed a $100 million term sheet for exclusive, perpetual U.S. rights to ALA-002, PharmAla Biotech’s next-generation MDMA therapeutic. Upfront consideration totals $3.33 million, split between $1.50 million cash and $1.83 million in JUNS shares, plus milestones and single-digit royalties.
Jupiter will escrow $600,000, usable as a reverse termination fee if no definitive agreement is signed within 90 days. ALA-002 is an FDA-recognized Novel Chemical Entity, designed for improved cardiovascular safety and reduced abuse liability versus racemic MDMA.
AI-generated analysis. Not financial advice.
Positive
- Exclusive, perpetual U.S. licensing rights to ALA-002 under a $100 million term sheet
- Upfront consideration of $3.33 million, including $1.50 million cash and $1.83 million in JUNS shares
- Single-digit royalties and development milestone payments tied to ALA-002 progress and commercialization
- ALA-002 recognized by FDA as a Novel Chemical Entity, supporting differentiated regulatory profile
- ALA-002 engineered for improved cardiovascular safety and reduced abuse liability versus racemic MDMA
- Positioning within projected multi-billion-dollar U.S. psychedelic therapeutics market for PTSD, anxiety and depression
Negative
- $600,000 escrowed as reverse termination fee if no definitive agreement within 90 days
- Transaction subject to due diligence, definitive documentation, corporate and regulatory approvals
- Equity component of $1.83 million in JUNS shares implies shareholder dilution at closing
Key Figures
Market Reality Check
Peers on Argus
JUNS was down 3.7% pre‑announcement while key biotech peers were mixed (e.g., BTAI -6.09%, SER +5.23%, VTVT +4.38%), indicating stock‑specific dynamics rather than a unified sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 04 | Investor summit presentation | Neutral | +3.3% | Announced participation in Market Movers Investor Summit to present company story. |
| Apr 13 | Conference appearance | Neutral | -1.4% | Planned presentation at Centri Capital Conference outlining performance and growth plans. |
| Apr 07 | Advisory board additions | Positive | +2.6% | Added experts to Nugevia advisory board to support nutraceutical commercialization. |
| Mar 31 | Emerging Growth talk | Neutral | +15.8% | Emerging Growth Conference presentation on clinical and commercial progress for JOTROL. |
| Mar 02 | BIO summit presentation | Neutral | -4.4% | BIO summit appearance highlighting FDA‑cleared IND and Phase IIa Parkinson’s program. |
Recent news flow has been dominated by conferences and visibility events, which often coincided with modest positive price reactions, despite ongoing financing and going‑concern risks in filings.
Over the past six months, Jupiter focused on visibility and pipeline positioning. Multiple investor conferences from March–May 2026 highlighted its JOTROL™ CNS program and early commercialization of the Nugevia supplement line. An advisory board addition in early April 2026 emphasized commercial distribution expertise. In parallel, SEC filings in April–May 2026 detailed substantial losses, a stockholders’ deficit, going‑concern language, Nasdaq non‑compliance notices, and reliance on equity and convertible notes. Today’s ALA‑002 term sheet adds a new CNS/psychedelic asset on top of that already capital‑constrained backdrop.
Regulatory & Risk Context
The company has an effective Form S-3 shelf filed on 2026-04-15, allowing up to $100,000,000 of securities to be issued via multiple offerings; at least 2 prospectus supplements (424B3) have already been filed, indicating active use of this financing capacity.
Market Pulse Summary
This announcement outlines a term sheet granting JUNS exclusive U.S. rights to ALA‑002, a non‑racemic MDMA NCE positioned within a projected $6–15 billion psychedelic therapeutics market. The deal structure includes a $3.33 million upfront mix of cash and stock, escrow protections, milestones, and royalties. Context from recent SEC filings shows limited cash, ongoing losses, an effective $100,000,000 S‑3 shelf, and going‑concern language, so investors may watch how JUNS finances development and manages dilution while integrating this asset with its CNS pipeline.
Key Terms
lock-up period financial
reverse termination fee financial
mdma-assisted therapy medical
AI-generated analysis. Not financial advice.
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine
JUPITER, FL, May 20, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, today announced that it has entered into term sheet to acquire exclusive, perpetual United States licensing rights to ALA-002, the lead drug candidate of PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) ("PharmAla"), a global leader in the research, development, and manufacturing of novel MDXX-class molecules. Pursuant to the term sheet, Jupiter would make to PharmAla an upfront payment of
ALA-002 is a patented, non-racemic MDMA formulation recognized by the U.S. Food and Drug Administration ("FDA") as a Novel Chemical Entity ("NCE"). It has been engineered to deliver materially improved cardiovascular safety and reduced abuse liability compared to racemic MDMA, while preserving and enhancing the pro-social and therapeutic properties central to MDMA-assisted therapy. PharmAla's MDMA supply is in active U.S. government-sponsored VA and DHA clinical trials, providing real-world manufacturing support addressing a $multi-Billion psychedelic therapeutics market targeting millions of Americans with PTSD/anxiety.
On April 18, 2026, President Donald J. Trump signed a landmark Executive Order titled "Accelerating Medical Treatments for Serious Mental Illness," directing the FDA and Drug Enforcement Administration ("DEA") to expand access to investigational psychedelic therapies. Key provisions of the Executive Order include the Right to Try Pathway: Establishes access to investigational psychedelic drugs for eligible patients, including Schedule I handling authorizations for treating physicians, Commissioner's National Priority Vouchers: Issued to psychedelic drugs that have received FDA Breakthrough Therapy designation, enabling expedited review timelines of 1-2 months vs. the standard 6-12 months, Federal Funding: Allocates
With ALA-002, Jupiter is positioning itself within what many analysts now project will become a multi-billion-dollar regulated psychedelic therapeutics market in the United States alone, with annual sales potential in the early-to-mid 2030s commonly estimated in the approximately 6 billion to 15 billion dollar range, led by MDMA- and psilocybin-assisted therapies for depression, PTSD, and anxiety disorders. Against this backdrop, a next-generation, non-racemic MDMA NCE such as ALA-002 offers Jupiter an opportunity to participate in the most advanced and clinically validated segment of psychedelic medicine, where MDMA-assisted therapy is widely expected to anchor one of the largest and fastest-growing indications in the category as reimbursement, clinic infrastructure, and federal initiatives converge to support scaled access for U.S. patients.
"This proposed transaction is strategically aligned with Jupiter's long-term focus on CNS innovation and the development of therapies intended to address Longevity, brain health, neuroplasticity, and serious neuropsychiatric conditions," said Christer Rosén, Chairman and Chief Executive Officer of Jupiter Neurosciences. "Substantial time and negotiations with the Pharmala team as well as our initial due-diligence of ALA-002 convinced us that with exclusive US rights to ALA-002, Jupiter would be adding a highly differentiated Mental Health asset that complements our broader mission of advancing novel treatments across the CNS landscape."
"ALA-002 represents the type of innovative, next-generation asset we believe can play a pivotal role in future neuropsychiatric therapies," said Alison Silva, President and Chief Business Officer of Jupiter Neurosciences. "The completion of this transaction would broaden our strategic reach in CNS and brain plasticity while strengthening our shareholder’s equity and create a potential path to build long-term value through disciplined clinical and regulatory execution in the United States."
"PharmAla has developed ALA-002 with the goal of delivering a differentiated MDMA-based therapeutic candidate for patients who need better treatment options," said Nicholas Kadysh, Founding Chief Executive Officer of PharmAla Biotech Holdings Inc. "Jupiter's focus on CNS disorders and its commitment to advancing innovative brain therapies in the United States make this a strong strategic fit for both companies."
D. Boral Capital, LLC is acting as the sole financial advisor to Jupiter Neurosciences in connection with this transaction.
The proposed transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company advancing a therapeutic pipeline targeting central nervous system disorders and neuroinflammation. The Company's lead program, JOTROL(TM) -- a proprietary, enhanced bioavailability resveratrol formulation -- is currently in a Phase IIa clinical trial for Parkinson's disease. JUNS also commercializes Nugevia(TM), a consumer longevity supplement. The acquisition of ALA-002 U.S. rights further strengthens the Company's CNS pipeline by adding a next-generation, patented psychedelic NCE at a pivotal moment in U.S. regulatory policy. For more information, please visit www.jupiterneurosciences.com.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules. PharmAla is the world's only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials, with a commercial presence through its Cortexa joint venture in Australia -- the only jurisdiction globally where MDMA is currently approved for prescription by authorized psychiatrists for the treatment of PTSD. PharmAla's LaNeo(TM) MDMA is supplied into multiple U.S. VA and DHA-sponsored clinical trials. For more information, please visit www.pharmala.ca.
About D. Boral Capital, LLC
D. Boral Capital LLC is a premier, relationship-driven global investment bank headquartered in New York. The firm is dedicated to delivering exceptional strategic advisory and tailored financial solutions to middle-market and emerging growth companies. With a proven track record, D. Boral Capital provides expert guidance to clients across diverse sectors worldwide, leveraging access to capital from key markets, including the United States, Asia, Europe, the Middle East, and Latin America. A recognized leader on Wall Street, D. Boral Capital has successfully aggregated approximately
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. Forward-looking statements include, without limitation, statements regarding the timing of definitive agreements with PharmAla, if entered into, the anticipated benefits of the proposed ALA-002 acquisition; expected development timelines; anticipated regulatory approvals, and the anticipated impact of President Trump's April 18, 2026 Executive Order on the psychedelic medicine sector and the Company's business. Such statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially, including, without limitation, that the proposed transaction is subject to the completion of due diligence, negotiation and execution of definitive agreements, receipt of all required corporate and regulatory approvals, and other customary closing conditions. The forward-looking statements contained in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Jupiter’s Annual Report on Form 10-K, filed with the SEC on April 1, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by applicable law. Investors are cautioned not to place undue reliance on forward-looking statements.
Investor Relations Contact
Jupiter Neurosciences, Inc.
Christer Rosen, Chairman & Chief Executive Officer
ir@jupiterneurosciences.com
Media Contact
Josh Birch, Media Relations Manager
KNB Communications
JBirch@KNBComm.com
SOURCE: Jupiter Neurosciences, Inc.
(c) 2026 Jupiter Neurosciences, Inc. All rights reserved. JOTROL(TM) and Nugevia(TM) are trademarks of Jupiter Neurosciences, Inc. LaNeo(TM) is a trademark of PharmAla Biotech Holdings Inc.
